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OBJECTIVE—Wesoughttodeﬁnetheprevalenceofnonislet,organ-speciﬁcautoantibodiesat
diagnosis of type 1 diabetes and to determine the prevalence of comorbid autoimmune diseases.
RESEARCH DESIGN AND METHODS—Children (n =4 9 1 )d i a g n o s e dw i t ht y p e1
diabetes at the Barbara Davis Center for Childhood Diabetes were screened for autoimmune
thyroid disease (thyroid peroxidase autoantibodies [TPOAb]), celiac disease (tissue transgluta-
minase autoantibodies [TTGAb]), and Addison disease (21-hydroxylase autoantibodies
[21OHAb]).
RESULTS—Of the 491 children, 161 had at least one nonislet autoantibody,and of these, 122
(24.8%) were positive for TPOAb, and 15 of the 122 (12.3%) had autoimmune thyroid disease.
There were 57 (11.6%) who were positive for TTGAb, of whom 14 (24.6%) had celiac disease.
Five (1.0%) were positive for 21OHAb, of whom one had Addison disease.
CONCLUSIONS—Many autoantibody-positive subjects present with additional auto-
immune disorders. Detection of these autoantibodies at type 1 diabetes onset may prevent
complications associated with delayed diagnosis of these disorders.
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T
ype 1 diabetes occurs in one in 300
individuals(1)andisassociatedwith
other autoimmune diseases, includ-
ing autoimmune thyroid disease (AIT)
in 15–30%, celiac disease (CD) in 4–9%,
and Addison disease (AD) in 0.5% (2); de-
tection of which is crucial to prevent mor-
bidity related to unrecognized disease.
Assaysforthyroidperoxidaseautoantibodies
(TPOAb) in AIT, tissue transglutaminase
autoantibodies (TTGAb) in CD, and 21-
hydroxylase autoantibodies (21OHAb) in
AD, may be used to screen for asymptom-
aticdiseasetoidentifyriskofprogressionto
overt disease. Previous studies have exam-
ined multiple autoantibodies in cohorts of
patientswithtype1diabetes(3).Wesought
to deﬁne the prevalence of nonislet, organ-
speciﬁc autoantibodies at the diagnosis of
type 1 diabetes and to determine the prev-
alence of comorbid autoimmune diseases.
RESEARCH DESIGN AND
METHODS—We studied 491 individ-
uals with type 1A diabetes diagnosed by
the American Diabetes Association crite-
r i a( 4 )a tt h eB a r b a r aD a v i sC e n t e rf o r
Childhood Diabetes from 2004 to 2009.
GAD antibody (GADAb), islet cell anti-
body (ICA512Ab), insulin autoantibody
(IAA), and zinc transporter 8 antibody
(ZnT8Ab) were used to conﬁrm the diag-
nosis of type 1 diabetes and were mea-
sured as described (5,6). TPOAb, TTGAb,
and 21OHAb were measured within a
mean 6 SD of 16 6 39 days of diagnosis,
as described (7,8). TPOAb was measured
using a RIA kit (KRONUS Inc., Star, ID).
Patients were diagnosed with AIT, CD,
and/or AD within 45 6 43 days of type
1 diabetes diagnosis. HLA class II DQAB
genotyping was performed on 457 sub-
jects for whom DNA was available, as
described (9). Subjects were enrolled
with informed consent, and the study
was approved by the University of Colo-
rado Institutional Review Board.
Our current clinical practice is to ob-
tain thyroid-simulating hormone (TSH)
and thyroid hormone levels (T4 or free
T4) biannually or with symptoms of AIT.
TPOAb screening is solely for research
purposestoidentifyindividualswithAIT.
Subjects with positive TPOAb were de-
ﬁnedashavinghypo-orhyperthyroidism
according to abnormal results of labora-
tory testing or by treatment, or both. The
date of TSH abnormalities was recorded
as the onset of AIT.
Patients with symptoms or persistently
high TTGAb were referred to gastroenter-
ology for evaluation and a small-intestinal
biopsy to conﬁrm CD diagnosis. Several
subjects refused the conﬁrmatory small-
intestinal biopsy, and CD was diagnosed
by two positive TTGAb results at an index
of .0.05 (10) and a gluten-free diet.
None of the patients with positive TTGAb
who were not diagnosed with CD had a
small-intestinal biopsy, and thus it is pos-
sible that some children might have had
undiagnosedCD.Individualswith positive
21OHAbhadACTHstimulationtesting,as
previously described (11).
GraphPadPrism5.00software(Graph-
Pad Software, San Diego, CA) was used for
statistical analysis. Descriptive statistics are
reported as the mean 6 SD. Proportions
were compared using a x
2 test unless
20% of the cells had an expected value of
,5,in which case the Fisher exact test was
used. Results were considered statistically
signiﬁcant with a , 0.05.
RESULTS—Of the 491 children diag-
nosed with type 1 diabetes, 408 (82.7%)
werenon-Hispanic white and262(53.4%)
were boys. The mean age of type 1 di-
abetes diagnosis was 9.6 6 4.4 years, and
theaverageHbA1catdiagnosiswas11.66
2.6%. Upon diagnosis of type 1 diabetes,
160children(32.6%)hadatleastonepos-
itive nonislet organ-speciﬁc autoantibody
(TPOAb, TTGAb, or 21OHAb; Fig. 1),
and 122 (24.8%) were positive for
TPOAb, of whom 15 (12.3%) had AIT.
Five (1.0%) were positive for 21OHAb,
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in 57 (11.6%), of whom 14 (24.6%) had
CD. Of these 14 diagnosed with CD, six
werediagnosedbyanalysis ofanintestinal
biopsy specimen and eight were diag-
nosed from two consecutive TTGAb re-
sults at an index of .0.05 (10) and
report of symptoms or gluten-free diet,
or both. The mean initial TTGAb for these
eight subjects was 0.88 6 0.33 (99th per-
centileofnormal=index0.05).Ofthe161
children with at least one nonislet, organ-
speciﬁc autoantibody, 30 (18.6%) were
diagnosed with an additional autoimmune
disease within an average of 46 6 43 days
of presentation. The HLA-DR3 allele was
found 33 of 53 (62.3%) of TTGAb
+ sub-
jects compared with 181 of 457 (44.8%)
TTGAb
– children (P =0 . 0 1 2 ) .
CONCLUSIONS—This study has
conﬁrmed the high prevalence of non-
islet, organ-speciﬁc autoantibodies in in-
dividualswithtype1diabetesandindicates
that for many, these autoantibodies are
presentatdiagnosis.Previousstudieshave
conﬁrmed the prevalence of these anti-
bodies (3) and the effect of these autoanti-
bodies on type 1 diabetes control (12).
Additionally, within an average of 45 days
after type 1 diabetes diagnosis, 19% of
individuals with nonislet, organ-speciﬁc
autoantibodies were diagnosed with clin-
ical disease. These comorbid conditions
were likely present at type 1 diabetes on-
set, given clinical practice to repeat posi-
tive autoantibody tests and perform
conﬁrmatory testing, which may take sev-
eral months to coordinate.
Twice as many children were positive
for TPOAb as TTGAb. However, an equal
number of children were diagnosed with
CD as with AIT. Analysis of HLA con-
ﬁrms a relationship between the HLA-DR3
allele and TTGAb positivity (7). Further
genetic typing will be important to iden-
tify additional genes that may contribute
to the presence of organ-speciﬁca u t o -
immunity and development of disease.
This study is limited because it only
monitoredsubjectsforashortperiodafter
their diagnosis of type 1 diabetes, and
conﬁrmatory small-intestinal biopsies for
CD were not performed on all TTGAb
+
subjects.
Ongoingfollow-upofthiscohortwill
be important to determine the natural
history of organ-speciﬁc autoimmunity
in patients with type 1 diabetes. Key
questions remain, including the inci-
dence of autoantibodies over time, the
evolution from positive antibodies to
disease, the genetic inﬂuences on auto-
immunity and disease, and patient char-
acteristics that may inﬂuence antibody or
disease development.
The strategy for screening for these
autoantibodies is a source of ongoing de-
bate (13–1 5 ) .H o w e v e r ,g i v e nt h eh i g h
preponderance of these antibodies at the
onset of type 1 diabetes, we recommend
screening for AIT, CD, and AD.
We have shown that 32.6% of pa-
tients with type 1 diabetes are positive
for at least one additional organ-speciﬁc
autoantibody at the diagnosis of type 1
diabetes, and 18.6% had clinical disease.
This is important for the clinical care of
patients with type 1 diabetes and may
provide insight into the pathogenesis of
these complex diseases.
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